Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A-101 topical solution in common warts
NCT03691831Phase 3Completed
- Sponsor
- Aclaris Therapeutics, Inc.
- Start
- Sep 2018
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of hydrogen peroxide gel in common wart (2 arms), sponsored by Aclaris Therapeutics, Inc. Primary endpoint: Number of Subjects Whose Identified Common Warts Are Determined to be Clear on the PWA Scale (PWA=0) at Visit 10 at Day 60. Started Sep 2018; status: completed.
02
Drugs
hydrogen peroxide gel
03
Conditions
common wart
Beyond the preview
Go deeper on NCT03691831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03691831.